An anti‐factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A

Autor: Takeyama, Masahiro, Nogami, Keiji *, Matsumoto, Tomoko, Noguchi‐Sasaki, Mariko, Kitazawa, Takehisa, Shima, Midori
Zdroj: In Journal of Thrombosis and Haemostasis April 2020 18(4):825-833
Databáze: ScienceDirect
Externí odkaz: